Healionics
Healionics develops vascular grafts and biomaterial scaffolds for safer and more reliable bloodstream access in dialysis patients with kidney failure. Its STARgraft vascular graft is designed to resist occlusion and infection, aiming to improve patient health and reduce the cost of dialysis care. The company’s STAR biomaterial platform supports tissue regeneration while minimizing scarring and infection in implantable devices.
Facts
- HQ
- Seattle, Washington
- Sectors
- Medical Device
- Founded
- 2007
- Type
- Corporation Seattle business license
- Employees
- 9
- Registered name
- Healionics Corp Seattle business license
- Total raised
- $18.2M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $2M · Dec 2025 SEC Form D
Is this your organization? Claim it
Healionics Raises $5.5M to Complete Human Trial of STARgraft Artificial Blood Vessel for Dialysis Patients
Healionics, a Seattle-based medical tech company, raised $5.5 million to complete human trials and pursue regulatory approval for its STARgraft artificial blood vessel designed for dialysis patients. The STARgraft aims to provide a durable vascular access solution resistant to blockages and infections that commonly affect dialysis patients.
Healionics raises $4.7M led by Keiretsu Capital to commercialize STARgraft artificial blood vessel, aims for early‑next‑year launch
Seattle medical device company Healionics raised $4.7 million led by Keiretsu Capital to commercialize STARgraft, a synthetic vascular graft designed to resist occlusion for dialysis patients, and plans a commercial launch early next year. The funding will finance a second human study and FDA clearance efforts; the company also converted $5.2 million of notes and interest into equity.
